FASN and hepatocellular carcinoma: All these suggested that lipid metabolism in HCC cells is affected by Hsp90 inhibitors, possibly due to regulatory effects between Hsp90 and lipid metabolism-related enzymes that are altered after Hsp90 inhibition, especially FASN, which produces C16:0.